Ispire Technology Inc

NASDAQ:ISPR

Earnings Call Analysis

Robust Sales Growth Despite Widening Net Loss

The company's total revenue surged to $41.7 million, up 30% year-over-year thanks to a 149% increase in cannabis hardware sales. A new celebrity partnership is set to boost the brand, targeting 40% gross margins through Malaysian operations efficiency. They have an ambitious revenue projection of $80 million to $90 million for cannabis hardware and $95 million to $105 million for tobacco vaping products in FY2024. Despite the sales upswing, the net loss widened to $4 million. The cash position appears stable with $27 million on hand, but operational investments will expand and are aimed at reaching breakeven cash flow in the future.

Remarkable Revenue Growth with Strategic Brand Collaborations

The company's overall sales reached a notable $41.7 million, marking an impressive 30.7% increase over the same period in the previous year, driven by a strategic focus on precision dosing technology and high-quality customer service. A standout example of this growth is the 149% surge in cannabis hardware revenue to $19.5 million. Additionally, the launch of the BRKFST-branded high-tech wafer products, in collaboration with Burna Boy, further expanded the company's global brand presence and partnership portfolio.

Operational Excellence and Expansion

A substantial operational highlight is the ISO and GMP certifications obtained for the company's new Malaysian manufacturing facility, a critical step in improving operational efficiency and expanding gross margin and profitability. With the facility operational, the company anticipates a meaningful financial performance boost starting from the next quarter. This initiative underscores the company's commitment to achieving a gross margin goal of over 40% for products manufactured in Malaysia, showcasing a forward-looking approach to financial enhancement and sustained growth.

Leveraging U.S. Market Potential with Regulatory Pursuits

The company is actively pursuing premarket tobacco product applications (PMTA) with the FDA to establish its presence in the U.S. e-cigarette market, which could unlock access to the lucrative $80 billion U.S. nicotine market. This move aligns with the company's innovation-driven brand strategy and leverages its increasing brand recognition within the United States.

Innovative Ventures and Technology for Market Differentiation

Post-quarter, the company formed a joint venture with Berify, capitalizing on blockchain technology to develop innovative age-verification solutions. This collaboration aims to intertwine advanced technologies with the company's e-cigarette hardware, potentially securing a competitive edge in the cannabis and e-cigarette vapor device markets.

Financial Insights: Increased Investments and Expenses

Although the company faced a net loss of $4.0 million for the fiscal second quarter of 2024 in comparison to a $0.1 million loss in the same quarter of the previous year, this mirrors strategic investments in operations and a roadmap for financial growth. In correspondence with these developments, operating expenses climbed to $10.3 million, reflecting a conservative approach to the accounts receivable reserve and additional costs related to marketing, trade shows, and maintaining the Malaysian manufacturing plant.

Liquidity and Working Capital Status

The company reported working capital of approximately $25 million, which showcases its continued ability to fund operations and growth initiatives despite the decrease from the previously reported quarter.

Earnings Call Transcript 2024-Q2

[Operator]

Hello, everyone, and welcome to today's conference call to discuss Ispire's financial results for its fiscal second quarter 2024 ended December 31, 2023. At this time, I would like to inform you that this conference is being recorded. [Operator Instructions] Joining us today are Mr. Michael Wang, the company's Co-CEO; and Mr. Daniel J. Machock, the company's CFO. First, Mr. Wang will brief you on the company's key highlights, and then Mr. Machock will review the company's financial results.

Before we begin, I would like to remind you that this conference call contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in its announcement are forward-looking statements. Forward-looking statements are based on estimates and assumptions made by the company in terms of its experience and its perception of historical trends, current conditions, and expected future developments, as well as other factors that the company believes are relevant.

These forward-looking statements involve known and unknown risks and uncertainties, and many factors could cause the company's actual results or performance to differ materially from those expressed or implied by the forward-looking statements. Further information regarding this and other risk factors are included in the company's filings with the SEC. The company undertakes no obligation to update forward-looking statements to reflect subsequent or current events or circumstances or to changes in its expectation, except as may be required by law.

I would now like to turn the call over to Mr. Wang. Mr. Wang, please go ahead.

[Michael Wang, executive]

Thank you, operator, and thank you all for joining us this morning. This quarter, we were pleased to accomplish many key operational and business milestones. Overall sales reached $41.7 million, an increase of 30.7% over the same 3-month period last year. The quarter also saw cannabis hardware revenue increase by 149% to $19.5 million compared to the same 3-month period last year. Our strategy of delivering best-in-class precision dosing technology and white glove customer service in these sectors has led to the increase in demand for our products and increased brand recognition. This increase in demand has been showcased by the rapid increase in cannabis hardware sales that we have been seeing quarter after quarter.

Another highlight is the recent launch of our BRKFST-branded high-tech wafer products in collaboration with Nigerian Afrobeats star, Burna Boy. The 5-year exclusive global manufacturing and distribution agreement marks our second celebrity/brand collaboration. Snoop Dogg's Dogg Lbs being the first such deal. It strengthened our portfolio of partnerships and our global brand presence. We will launch BRKFST products in Africa in Q1 this year, in Europe and the U.K. this summer, and in the Middle East later in the year.

Additionally, we were able to achieve ISO and GMP certifications for our new Malaysian manufacturing facility, which opened on February 1 of this year. Attaining such certifications is a sign for our commitment to best practices at our plant. We believe that this facility will prove instrumental in enhancing our operational efficiency, and ultimately leading to improved gross margin and profitability. We expect to start seeing a meaningful impact from this facility on our financial performance as early as next quarter.

Our Malaysian operations provides the opportunity to streamline our supply chain. Based on our experience with related party factories, we believe that we can achieve our goal of more than 40% gross margin on products manufactured at the Malaysian operation. This operational initiative, in contrast to our previous arrangement involving third-party factories, represents a forward-thinking approach that aims to enhance our financial performance and drive sustained growth for the company.

In tandem with our strategic growth internationally, we have begun pursuing multiple PMTA, that is premarket tobacco product applications, with the FDA in order to build our domestic market E-cig presence and distribute our innovative E-cig products within the U.S. market. Receiving PMTA approval will give Ispire the opportunity to sell into the $80 billion U.S. nicotine market, diversify our product lines, and leverage our growing brand recognition in the U.S., the largest nicotine market in the whole world.

We plan to announce further details on this development in the coming months. Our brand continues to build upon our long-lasting recognition and visibility as Ispire solidifies itself as a leading, innovative, and premier precision dosing technology company. The positive reception and the customer loyalty we have garnered are reflective of the value associated with our ongoing innovations. Each quarter, we have witnessed tangible results, reflecting our dedication to customer-focused innovations.

Also subsequent to quarter end, we announced that we recently formed a joint venture with Berify, a pioneering platform leveraging the power of blockchain to redesign product authentication, consumer engagement, user identification, and access control. This joint venture will leverage Berify's multi-patented technology and Ispire's hardware expertise to introduce an innovative age-verification solution for cannabis and e-cigarette vapor devices, as well as the submission of PMTA applications that incorporate cutting-edge technologies such as next-generation e-cigarette hardware with point-for-use age-verification and educating technology that is both secure and user-friendly.

E-cigarettes, with an end-to-end range of dynamic features, such as authentication, direct-to-consumer engagement, and the exclusive offering, all built on the foundation of blockchain technology. The real-time biometric identity platform for user access control, creating added security and reliability that deters counterfeiting. We are very excited about the joint venture and the future potential it holds as we aim to grow our footprint as the leading precision dosing technology company.

Looking ahead to the remainder of fiscal year 2024, we are focused and committed to the steady trajectory of growth. Our strategic partnerships and innovation will position us to eventually enter the $80 billion U.S. nicotine market and strengthen our celebrity partnership portfolio worldwide. Our own manufacturing capabilities will expand our gross margin and profitability as we transition more of our production to the Malaysian operation.

With that, I will turn the call over to our CFO, Dan Machock, who will review and comment on our financial results.

[Daniel Machock, executive]

Thank you, Michael, and thanks to everyone for being on the call. Let's take a deeper dive into our financials. I will summarize some key financial results for the fiscal second quarter 2024. In my comments on the quarterly results, I will refer to the fiscal second quarter 2024 as the 3 months ended on December 31, 2023. All comparisons are to the prior year's 3 months ended December 31, 2022, unless otherwise stated.

As Michael mentioned, we achieved remarkable growth for the fiscal second quarter of 2024, including an all-time high for U.S. cannabis vaping hardware sales increasing by 149% to $19.5 million. Sales of tobacco vaping products were $22.1 million in the fiscal second quarter of 2024 versus $24.0 million for the same period the previous fiscal year. Overall, our total revenue for the 2024 fiscal second quarter increased by 30% to $41.7 million year-over-year.

For the 6-month period ended December 31, 2023, revenue increased to $84.5 million or 43% compared to the same period last year. Gross profit for the fiscal second quarter in 2024 rose to $6.3 million, representing a 24.1% increase compared to the same period of the previous fiscal year. We experienced a slight downtick in gross margin to 15.3% from 16.1% in the same period last year. The gross margin for tobacco vaping products was 15.3% for the fiscal second quarter of 2024 as compared to the 14.5% for the same period in the previous fiscal year.

During the 6-month period ended this quarter, gross profit increased to $13.3 million or by 33.6% year-over-year. Tobacco vaping products was 15.6% for the 6-month period ending the quarter as compared to 15.2% for the same period in the previous fiscal year. We are poised to improve our margins as we ramp up sales of the new model products throughout fiscal 2024.

The total operating expenses for the fiscal second quarter of 2024 increased by 114% to $10.3 million compared to $4.8 million for the same period the previous year. Operating expenses for the 6-month period increased by 67% to $18.1 million. The increase in expenses was due primarily to an increase in reserving for accounts receivable. This was due to us adopting a new accounting policy, ASU 2016-13 CECL, which was effective July 1, 2023.

It is our belief that customers are all collectible, but we have taken a conservative approach to our accounts receivable reserve. This increase in operating expenses was also due to marketing expenses, trade shows, and working capital relating to maintaining our manufacturing plant in Malaysia and increased professional fees for expenses incurred being a public company.

As a result of the foregoing, our net loss was $4.0 million for the fiscal second quarter 2024 as compared to $0.1 million for the fiscal second quarter 2023. This increase is indicative of our increased investments in our operational efficiencies this quarter and our strategic financial growth path. Net loss for the 6-month period ending December 31, 2023, was $5.4 million as compared to $2.1 million for the same period in the previous year.

Turning to the balance sheet and liquidity. As of December 31, 2023, and June 30, 2023, we had working capital of $24.8 million and $28.8 million, respectively. We believe that our current cash and cash flow generated from our operations will be sufficient to meet our working capital needs for the next 12 months. Net cash used in operating activities was $20.2 million for the 6-month period ended December 31, 2023, compared to the net cash provided by operating activities of $8.4 million for the same period last year. Net cash used in investing activities was $1.9 million compared to $0.5 million for the same period last year. Net cash used in financing activities was $0.7 million compared to $1.9 million provided by financing activities for the same period last year.

This concludes our fiscal second quarter 2024 financial results review. I will now turn it back over to Michael. Michael?

[Michael Wang, executive]

Thanks, Dan. Before we open the call to questions, I would like to expand on how our above-mentioned key strategies relate to our long-term financial goals. As we move forward in fiscal year 2024, we believe our strategic investments and the continued innovation position us for sustained growth. On that front, for the current fiscal year, that's fiscal year 2024, we expect cannabis vaping hardware revenue to build upon their strong performance with revenue projected to generate between $80 million and $90 million. That represents another 100% to 125% growth rate over the last fiscal year.

On the other hand, the revenue for tobacco vaping products for the fiscal year 2024 is projected at $95 million to $105 million, representing a growth rate of 33% to 47%. With the launch of our global E-cigarette distribution partnerships with the celebrities and brands, we expect our e-cigarette revenue to pick up pace in calendar year 2024 and 2025.

Innovation remains at the core of our philosophy. We will continue to channel resources to stay at the forefront of the market's needs and expectations, to solve consumer and customer pain points, to expand our reach, and to enhance our offerings. We are determined in our commitment to our shareholders and customers alike, determined to deliver superior products and sustained value in the quarters ahead.

In the meanwhile, if you have any questions, please contact us through e-mail at [e-mail]. Operator, this completes our prepared remarks, and we are now open to questions. Please go ahead.

[Operator]

[Operator Instructions] Our first question comes from the line of Bo Pei with US Tiger Securities.

[Bo Pei, analyst]

I have a couple. So the first question is about tobacco revenue. So tobacco revenue declined sequentially. Can you discuss the drivers? And then given the fiscal year-to-date tobacco revenue to achieve the fiscal year guidance midpoint, which is $100 million, the company will have to generate at least $26 million tobacco revenue in the last 2 quarters per quarter. So can you also share some colors why you are confident in achieving this implied growth? And I have a follow-up.

[Michael Wang, executive]

Okay. Bo, thank you. Good question there. Yes, tobacco side, because we use distributors to distribute products to retailers, naturally, here and there, there will be fluctuation from 1 quarter to the other. As you recall, last quarter was a real good quarter for tobacco revenue. It increased by almost 50% over same period last year. So unfortunately, this quarter or this recent quarter, we saw a bit of a dip. It dropped by 8% from the same period last year. However, we are very confident, if you average, I would say, quarterly numbers, we will still see a significant growth.

So Second question, you asked about our confidence in delivering $26 million per quarter for 2 quarters straight in order to hit the guidance. We are very confident that can be achieved for a couple of reasons, though. All tobacco products have been open systems, by and large, open systems sold in Europe. That's where the main revenue segment is. Europe is our primary market for open systems.

As you probably heard, France and the U.K. announced the banning of disposable E-cigarette, and both actually already took effect, especially the U.K. market reacted really strongly towards that banning -- the ban of the disposable devices -- in both markets. And also, European Union is considering a similar EU-wide ban of disposables. So all factors indicate that the open systems that we have been marketing and selling will actually gain strong, I would say, momentum through this change in regulation. In the future quarters, we expect to see increase in our E-cig sales there. That is 1 key factor.

Second factor is really more, say, celebrity/brand E-cigarette business that we don't have a revenue for so far. We will see some contribution from that front between now and fiscal year. So those 2 factors combined give us that confidence. So back to you.

[Bo Pei, analyst]

That was helpful. And then my second question is, I remember last quarter, the management expected the cannabis gross margin to start improving in the December quarter, but the cannabis gross margin actually declined a little bit from the September quarter. So what caused the actual results to diverge from your previous outlook? And then do you still believe we can achieve the 40% gross margin for cannabis business within the next 15 months.

[Michael Wang, executive]

Well, first part of your question, why did the gross margin for cannabis decrease over the same period last year. Yes, indeed, there were a few key factors that drove that change. Number 1 is really I would categorize as, before Chinese New Year holidays, all the factories tend to shut down their plants, typically 1 week before Chinese New Year, and that lasts typically 10 days after Chinese New Year. So during that shutdown and even before that shutdown, factories really couldn't commit to, let's say, additional capacity or couldn't commit to more orders.

So in the December quarter, we obviously experienced the same challenge. During that time, we had to -- on one hand, we had increased demand from market; on the other hand, we had challenge being factories completing the product and shipping them in time. So several others incurred higher expenses, including, for example, shipping cost. Shipping cost has really increased tremendously between China and the U.S. So that affected our gross margin somewhat. I would say that's probably contributor #1 to the decrease in gross margin. That combined with several other factors drove gross margin down by, I think, over 2 points.

So the second part of your question is how confident we are with getting to 40% gross margin after Malaysian operation should start its production. So it's really a capacity issue, Bo. Previously, we communicated our goal was, in 18 months' time, to transition most, if not all, say, production of cannabis vaping hardware from our related party factories in China to Malaysia. So that is still our goal. However, to get there, we need to make some, I would say, Phase 2 investment into the build-out for the Malaysian operation. That's still our commitment. The speed of getting there really depends on our working capital available to fund the expansion in Malaysia.

So once again, our internal goal is still to achieve majority of the production of cannabis vaping hardware in Malaysia versus in China factories. With that, obviously, our goal is to see a significant improvement in gross margin. Every piece of product based on our past knowledge and based on Malaysian operations cost analysis, would yield us 40% or even more in gross margin if that operation can take over all the production of products. So that's my long answer to your questions.

[Bo Pei, analyst]

Got it. Got it. That's helpful. And then my third question is about Ispire ONE. So can you share any updates on Ispire ONE? Has the order intake so far met your original expectation?

[Michael Wang, executive]

Ispire ONE was officially introduced to the market in early November. So far -- I would just share a couple of data points to indicate where everything is. Part of our strategy with Ispire ONE has always been to provide value-added products and services to large brands and MSOs, because those are the organizations that would see the benefit of Ispire ONE more clearly in terms of operating efficiency gain and brand reputation.

So that was part of our goal that we had in the back of our mind all the time. And the last 2.5 months prove that our approach or method, our strategy was spot-on. As of November 2023, we only had 2 customers that I would consider multi-state operators. As of now, we are entertaining another 6 MSOs since we launched Ispire ONE. So we don't have a major uptick in other volumes for Ispire ONE products yet, because most of the customers, especially MSOs, are taking their time to evaluate the products and the operating procedures.

And as we all know, larger MSOs tend to be more careful and conservative in the decision-making process. So that process we expect to take a while. But in the meanwhile, we are starting to get orders in from medium-size brands. So that's my answer to your question.

[Bo Pei, analyst]

Got it, Michael. And then also, I have a question on cash and cash equivalents. So I noticed the cash and cash equivalents declined again this quarter. So I mean, assuming we continue to burn cash at this rate, the company will probably run out of cash in a few quarters. And then you also mentioned we need to continue to invest in Malaysia, our factories. So what is the company's plan to manage the cash level going forward?

[Michael Wang, executive]

Okay. A couple of things. For us -- you are spot-on. Obviously, the cash burn has been to fund the growth of the company. And on the other hand, we are mindful -- as you pointed out, we are mindful of the available cash to continue the support of the Malaysian operation and so on and so forth.

First of all, we had just over $9 million worth of cash freed up 2 weeks ago. That used to be part of our investment in a certificate deposit account in Hong Kong. And that CD matured 2 weeks ago. So that dollar amount, just over $9 million, is freed up now. So as of now, as per the report, we had just over $17 million in cash. Adding the other $9.2 million to it. So we are now at $27 million in cash.

But the key answer I want to share with you, Bo, is our team has been working diligently, especially under the leadership of our CFO, Dan, in addressing the accounts receivable side. In the coming quarter, we should expect to have, I would say, much improved picture of accounts receivable. This is partially because the team has implemented a new deal review, credit review, what we call, deal desk, within the sales function. So that certainly made it much, much easier for us to negotiate with the customers based on the credit worthiness to minimize any potential exposure.

So with that deal desk, we are also very diligent with the payment terms. So on that front, I think in the coming quarters, we should see improvement. But by and large, as Dan pointed out in his part of the remarks, working capital at about $25 million is a drop of roughly $2.5 million from the previous quarter. So from that point of view, we are, on one hand, careful in managing our cash. On the other hand, we feel this still gives us enough runway. But on the other hand, though, I don't know if you saw that we filed registration to raise additional capital. So that is also going on. So we are addressing it both from cash management AR point of view and from investor point of view. Bo?

[Bo Pei, analyst]

Got it, Michael. That was helpful as well. And that actually led to my last question. So we also noticed accounts receivable continued to increase this quarter. And I understand you mentioned we're going to be more stringent in terms of customer credit worthiness. So can you share more color how you are going to collect this accounts receivable, especially given its significant size, because our cash balance is over $20-something million, but our accounts receivable is over $25 million. And then if we are going to be more stringent in terms of customer credit worthiness, will that impact our revenue growth for the cannabis business going forward?

[Michael Wang, executive]

Okay. Bo, I will provide a high-level answer. If it's not deep enough, Dan can jump in to share more. You are right about the AR side. So as you very well pointed out, growing revenue side and preserving cash certainly is a balancing act by itself. On one hand, we certainly strategically are more focused on medium-to-large accounts now than ever before. So that also helps with, I would say, risk exposure.

As we all know, with lack of, let's just call, banking services to the cannabis industry, cash management for our branded customers is also a big challenge. So generally, cash cycle in this industry could be anywhere between 6 months to even up to 8 months. So the smaller the brand, the bigger challenge they face. As we, in the last couple of years, have grown in revenue and reputation, we are able to attain much more desirable and more creditworthy larger brands. So from that point of view, that's why the deal desk serves a great deal in our decision process.

We feel, through the deal desk and through the type of customers we are working with, AR risk is going to get less and less. However, larger MSOs on the other hand also have the scale to demand a bit more favorable payment terms. So we are managing both aspects carefully. The typical deals or contracts include the payment plan. So basically, in addition to payment terms, for some of them, there is also -- even if they don't hear certain payment terms, they will need to get certain payment plan. There is minimum threshold there.

So all those factors together that happen in the finance and sales organization, I think, will certainly help us managing cash and managing collection. For a lot of the past due accounts, we also worked out payment plans with them, and we feel, more than ever, those accounts will complete their payment plans. So Bo, did I miss anything?

[Bo Pei, analyst]

No. Yes, I think that answers my question. And then my last question is on operating expenses. I noticed operating expenses increased over 30% from last quarter. Can you just share some color on the increase? And then, how should we think about the operating expenses level going forward like the next few quarters?

[Michael Wang, executive]

Yes. Dan probably can answer that question the best, but I will point out, before Dan answers your question. As Dan pointed out, one new element in the OpEx is reserved for AR. So I think that's probably the largest contributor. Dan, can you jump in and answer Bo's question there?

[Daniel Machock, executive]

Sure, Michael. We haven't really commented on future OpEx or future net loss, but we are excited to continue to invest in the initiatives that we spoke about on the call. Specifically, in Malaysia, with our tobacco initiatives, and just overall general OpEx in the United States, we'll continue to invest at the pace that we feel will continue to drive our revenue growth. I think we've proven that so far with our past few quarters, and we should see similar trend. We will see OpEx expand as gross margin expands, and that's something that we'll continue to monitor as we focus on breakeven cash flow at some point in the future. Hopefully, that answers your question.

[Bo Pei, analyst]

Yes, that was helpful. And that were all my questions. Thank you so much.

[Operator]

[Operator Instructions] There are no further questions at this time. And with that, this concludes today's teleconference. You may disconnect your lines at this time.